Literature DB >> 16887983

Impaired intracellular calcium mobilization and NFATc1 availability in tolerant anti-insulin B cells.

Carlos A Acevedo-Suárez1, Dawn M Kilkenny, Martha B Reich, James W Thomas.   

Abstract

B lymphocytes that recognize soluble self-Ags are routinely found in normal individuals in a functionally inactive or anergic state. Current models indicate that this tolerant state is maintained by interactions with self-Ags that uncouple the BCR from downstream signaling pathways and increase levels of free calcium. Contrary to this expectation, B cells that harbor anti-insulin Ig transgenes (125Tg) are maintained in a tolerant state even though free calcium levels remain normal and tyrosine kinase substrate phosphorylation is preserved following BCR stimulation. Under basal conditions, intracellular levels of inositol 1,4,5-trisphosphate are increased and NFATc1 levels are reduced in 125Tg B cells. The 125Tg B cells are markedly impaired in their ability to mobilize calcium upon stimulation with ionomycin, and BCR-induced calcium mobilization from internal stores is decreased. In contrast, poisoning intracellular calcium pumps with thapsigargin increases calcium mobilization in 125Tg B cells. Changes in calcium signaling are accompanied by a failure of 125Tg B cells to translocate NFATc1 into the nucleus following stimulation with either anti-IgM or ionomycin. Thus, disassociation of BCR from multiple signaling pathways is not essential for maintaining tolerance in anti-insulin 125Tg B cells. Rather, BCRs that are occupied by autologous insulin deliver signals that induce changes in intracellular calcium mobilization and maintain tolerance by preventing activation of key transcription factors such as NFAT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16887983     DOI: 10.4049/jimmunol.177.4.2234

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile.

Authors:  Ganna A Liubchenko; Holly C Appleberry; V Michael Holers; Nirmal K Banda; Van C Willis; Taras Lyubchenko
Journal:  J Autoimmun       Date:  2012-02-24       Impact factor: 7.094

2.  NFATc2 (NFAT1) assists BCR-mediated anergy in anti-insulin B cells.

Authors:  Rachel H Bonami; William T Wolfle; James W Thomas; Peggy L Kendall
Journal:  Mol Immunol       Date:  2014-02-06       Impact factor: 4.407

3.  Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.

Authors:  Yao Chen; Jinsong Zhang; Kwan-Ki Hwang; Hilary Bouton-Verville; Shi-Mao Xia; Amanda Newman; Ying-Bin Ouyang; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2013-07-03       Impact factor: 5.422

Review 4.  B cells and immunological tolerance.

Authors:  Nataly Manjarrez-Orduño; Tâm D Quách; Iñaki Sanz
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

5.  The regulation of autoreactive B cells during innate immune responses.

Authors:  Barbara J Vilen; Jennifer A Rutan
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Functional silencing is initiated and maintained in immature anti-insulin B cells.

Authors:  Rachel A Henry; Carlos A Acevedo-Suárez; James W Thomas
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

Review 7.  B-cell anergy: from transgenic models to naturally occurring anergic B cells?

Authors:  John C Cambier; Stephen B Gauld; Kevin T Merrell; Barbara J Vilen
Journal:  Nat Rev Immunol       Date:  2007-07-20       Impact factor: 53.106

8.  Silencing of high-affinity insulin-reactive B lymphocytes by anergy and impact of the NOD genetic background in mice.

Authors:  Mia J Smith; Rochelle M Hinman; Andrew Getahun; Soojin Kim; Thomas A Packard; John C Cambier
Journal:  Diabetologia       Date:  2018-09-25       Impact factor: 10.122

9.  Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.

Authors:  Wilton B Williams; Jinsong Zhang; Chuancang Jiang; Nathan I Nicely; Daniela Fera; Kan Luo; M Anthony Moody; Hua-Xin Liao; S Munir Alam; Thomas B Kepler; Akshaya Ramesh; Kevin Wiehe; James A Holland; Todd Bradley; Nathan Vandergrift; Kevin O Saunders; Robert Parks; Andrew Foulger; Shi-Mao Xia; Mattia Bonsignori; David C Montefiori; Mark Louder; Amanda Eaton; Sampa Santra; Richard Scearce; Laura Sutherland; Amanda Newman; Hilary Bouton-Verville; Cindy Bowman; Howard Bomze; Feng Gao; Dawn J Marshall; John F Whitesides; Xiaoyan Nie; Garnett Kelsoe; Steven G Reed; Christopher B Fox; Kim Clary; Marguerite Koutsoukos; David Franco; John R Mascola; Stephen C Harrison; Barton F Haynes; Laurent Verkoczy
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 17.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.